R. Andrew Eckert
Chairman of the Board
Andy Eckert has held a number of senior executive positions during his career. Between April 2017 and October 2019 he acted as the CEO of Acelity L.P., Inc., a global advanced wound care company. Acelity was sold to 3M in October 2019 for $6.7 billion. Prior to Acelity, Andy was the CEO of Valence Health, an emerging leader in value-based healthcare, which was acquired by Evolent Health in 2016. Prior to that he was CEO of TriZetto, a leader in Payer IT. Apax Partners sold TriZetto to Cognizant Technology Solutions Corporation in 2014 for $2.7B. Prior to TriZetto, Andy was Chairman and CEO of CRC Health Group, the leading behavioral health treatment provider owned by Bain Capital. CRC was sold to Acadia Healthcare in 2015 for $1.3B. Earlier in his career, Andy was CEO of Eclipsys Corporation ($500M HCIT company) from 2005-2009 and CEO of SumTotal Systems (e-learning) from 2002-2005. He started his career at ADAC Laboratories, a leader in Nuclear Medicine, PET and clinical IT where he spent 11 years, including 4 as Chairman and CEO until its sale to Philips Medical Systems in 2000.
Andy has served on a number of corporate boards. He is currently the Chairman of Varian Medical Systems and a member of the board of directors of Becton, Dickinson & Company.
Timothy E. Guertin
Timothy E. Guertin, has been a director of the company since 2005 and served as president and chief executive officer of the company from 2006 to 2012.
Mr. Guertin joined Varian in 1976 and since then has served in major management positions over his 30-plus years with the company. Prior to being appointed CEO in February, 2006, he served as Varian's president and chief operating officer. Mr. Guertin was named a corporate vice president in 1992 and executive vice president in 1999. At one time he was general manager and then president of Varian's Oncology Systems business, the company's largest business and the world's leading supplier of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. Prior to becoming head of the Oncology Systems business, he held a variety of positions, including general manager of customer support. He holds a BS in electrical engineering and computer sciences from the University of California at Berkeley.
Mr. Guertin is the current chairman of the Board of Directors of the AeA (American Electronics Association), a nationwide trade association that represents all segments of the technology industry, and he is a member of that organization's Silicon Valley/Northern California Council. He is also a member of the Board of Directors of the Diagnostic Imaging Section of NEMA (National Electrical Manufacturers Association), and he serves as chairman of NEMA's Therapy Systems Division. In addition, he sits on the corporate councils of the American Society of Therapeutic Radiology and Oncology (ASTRO), and the Canadian Association of Radiation Oncologists (CARO), professional organizations of radiation oncology clinicians.
SVP, Controller, CFO, Lilly Research Labs
Anat Ashkenazi, has served as senior vice president, controller and CFO at Lilly Research Labs since 2016. Over the past 17 years, she has held several executive positions at Eli Lilly and Company. In her current role, Ashkenazi leads a global team and oversees all business area CFOs, the corporate team responsible for financial planning and analysis, accounting and internal and external reporting, as well as the corporate strategy and business transformation teams. Ashkenazi earned a Bachelor of Arts in Economics and Business Administration from Hebrew University of Jerusalem. She also received a Master of Business Administration from Tel Aviv University.
Jeffrey R. Balser, MD, PhD
President and Chief Executive Officer at Vanderbilt University Medical Center (VUMC) and Dean of Vanderbilt University School of Medicine
Dr. Balser has served as President and CEO since 2016, and prior to the financial and legal separation of VUMC from Vanderbilt University, served as vice chancellor for health affairs and dean of medicine since 2009. During this period, he has led the Medical Center through a period of marked expansion of service volume, doubling the outpatient visit volume to over 2.3 million, expanding the children’s hospital and the adult critical care beds. Over the decade VUMC net revenues have more than doubled to over $4.3 billion, and with 23,000 employees is the largest private employer in middle TN. Prior to 2008, as VUMC’s chief research officer he led a period of scientific expansion that moved the School of Medicine into the nation’s top 10 in National Institutes of Health funding. Dr. Balser earned his medical and PhD degrees from Vanderbilt University and completed his residency and fellowship training in anesthesiology and critical care medicine at The Johns Hopkins Hospital. He also holds a Bachelor of Science degree in Engineering from Tulane University. He became a member of the National Academy of Sciences in 2009, and serves on the organization’s governing Council.
Judy Bruner joined the Varian Board of Directors on August 20, 2016. She is the retired Executive Vice President, Administration and Chief Financial Officer for SanDisk where she served from 2004 to 2016 when it was acquired by Western Digital. She has a strong track record and deep knowledge in corporate finance as well as a solid reputation with investors. Bruner also serves on the Board of Directors of Brocade Communications, Inc. where she is chair of the audit committee, the Board of Directors for Applied Materials, and the Board of Trustees of the Computer History Museum. She also served in the past on the boards of Vermillion, Inc. and SanDisk Corporation, before assuming her executive role there. Prior to joining SanDisk, Bruner held senior financial management positions with Palm, Inc., 3Com Corporation and Ridge Computer. She earned an MBA at the University of Santa Clara and a BA in Economics at UCLA.
Jean-Luc Butel has served as Senior Adviser to McKinsey Healthcare Practice since 2015. From 2012 to 2015, Butel served as Corporate Vice President and President of International at Baxter. He has held prior executive management positions at Medtronic, Johnson & Johnson, and Becton-Dickinson. Butel earned a BA in International Affairs from The George Washington University and a MBA in international management from the American Graduate School of International Management (Thunderbird). Butel is a member of the Board of Directors of the Singapore Economic Development Board and Takeda Pharmaceutical Company.
Regina E. Dugan, Ph.D.
Regina E. Dugan joined the Varian Board of Directors in December 2013. Currently serving as Senior Vice President of Engineering at Facebook, Inc., she has deep familiarity with a wide range of advanced technologies in defense and security, as well as commercial industries. She is an inventor or co-inventor on several patents and has a Ph.D. in Mechanical Engineering from the California Institute of Technology (Caltech).
Prior to her current position at Facebook, Dr. Dugan was the Senior Vice President of Advanced Technology and Projects at Google/Motorola Mobility. From July 2009 to March 2012, she served as the first female director at the Defense Advanced Research Projects Agency, the principal agency within the U.S. Department of Defense for research, development, and demonstration of high-risk, high-payoff capabilities.
Prior to that, she held numerous executive positions including:
- co-founder, president, and CEO at RedXDefense LLC, a security solutions company, 2009-2012
- co-founder, president, and CEO of Dugan Ventures, an investment firm where she is still serves as a non-voting partner, 2001-2009
Phil Febbo, MD
Chief Medical Officer, Illumina
Dr. Phil Febbo has served as CMO at Illumina since 2018 and is responsible for developing and executing the Company’s medical strategy to drive genomic testing into healthcare practice in order to improve health outcomes. Prior to joining Illumina, he served as CMO of Genomic Health for five years where he drove the company’s medical strategy, was accountable for the development of evidence supporting GHI’s proprietary tests, engaged with the payer community to drive reimbursement, and served as a corporate officer between 2016 and 2018. Prior to Genomic Health, Dr. Febbo was a Professor of Medicine and Urology at the University of California, San Francisco (UCSF), where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer, and his clinical practice focused on genitourinary oncology. He currently serves on the board of the American College of Medical Genetics and Genomics Foundation.
Dr. Febbo holds a Bachelor of Arts degree in Biology from Dartmouth College and an M.D. from UCSF. He completed his internal medicine residency at the Brigham and Women’s Hospital and his fellowship in oncology at the Dana-Farber Cancer Institute.
David J. Illingworth
David J. Illingworth joined the Varian board in August 2011.
Mr. Illingworth has had a long career in the medical technology sector in sales, operations, and general management roles based in the U.S., the U.K., and Asia. Most recently, from 2007 to 2011, he served as Chief Executive Officer at Smith & Nephew, an orthopedic devices company with annual revenues of $4.0 billion. Mr. Illingworth previously held a variety of executive positions including:
- chief operating officer and division president at Smith & Nephew (2002-2007)
- president and chief operating officer at XL Vision (2000-2002)
- chairman, president, chief executive officer, and executive chairman at VidaMed (1998-2000)
- vice president, executive vice president, and business unit president at Nellcor Puritan Bennett (1993-1998)
- managing director, GE Medical Asia and general manager, western region, GE Medical Systems (1978-1992)
Michelle Le Beau, MS, PhD
Professor of Medicine, University of Chicago and director, University of Chicago Medicine Comprehensive Cancer Center
Dr. Le Beau holds numerous positions at the University of Chicago, including Arthur and Marian Edelstein Professor of Medicine, Section of Hematology/Oncology (1986—present); Director, University of Chicago Medicine Comprehensive Cancer Center (2004—present); Board Member of the University of Chicago Medicine Cancer Council (2012—present); Director, Cancer Cytogenetics Laboratory (1986—present).
Dr. Le Beau holds a PhD and an M.S. in human genetics and experimental pathology from the University of Illinois at Chicago and a B.S. from Purdue University, and is board-certified in clinical cytogenetics by the American Board of Medical Genetics and Genomics.
Dow R. Wilson
President and Chief Executive Officer (CEO)
Dow R. Wilson is president and chief executive officer of Varian Medical Systems and a member of the company's Board of Directors.
Mr. Wilson has held key executive positions since joining Varian in 2005. Prior to being appointed CEO, he served as corporate executive vice president and chief operating officer and president of Varian’s Oncology Systems business.
Mr. Wilson joined Varian following a 19-year career with General Electric, in a variety of senior management positions. Most recently, he served as CEO for GE Healthcare-Information Technologies. Prior to that, he was general manager for a number of businesses, including the X-Ray, Functional Imaging, Computed Tomography (CT), and Positron Emission Tomography businesses.
A graduate of Brigham Young University, Wilson also holds an MBA from the Amos Tuck School of Business at Dartmouth.